9 juni 2013: Helpt neupogen of neulasta wel tegen neutropenie - tekort aan witte bloedlichaampjes - veroorzaakt door chemo? En zijn er niet toxische natuurlijke alternatieven voor?

Chemo veroorzaakt vaak neutropenie, een vermindering van de witte bloedlichaampjes. Vaak krijgen wij de vraag wat kun je daartegen doen. Zijn er natuurlijke middelen die dit tegen kunnen gaan? In de reguliere oncologie wordt dan vaak neupogen - filgrastim of nog beter werkzaam neulasta - pegfilgrastim toegediend., een kunstmatige vorm van G-CSF  (kolonie stimulerende factor).

Orthomoleculaire artsen zeggen dat ook niet toxische natuurlijke middelen neutropenie kan tegengaan, maar welke middelen en voedingstoffen dat zijn lijkt het me beter dat u daarvoor een goed gekwalificeerde orthomoleculaire arts consulteert want ik denk dat dit bij elke persoon en ook wel per chemo en vorm van kanker kan verschillen. We horen van veel patiënten dat chemosupport - een mix van bepaalde kruiden -  van de natuurapotheek de bijwerkingen van chemo tegengaat bij met name chemo bij darmkanker, maar ook hiervoor raadpleeg aub de natuurapotheek zelf of een arts.

Dat Filgrastim en vooral Pegfilgrastim invloed heeft op de effectiviteit van de chemokuren en wel of niet optreden van neutropenie en zelfs op de mediane overleving wordt beschreven in een grote review studie uit 2011 Granulocyte colony-stimulating factors for febrile neutropenia prophylaxis following chemotherapy: systematic review and meta-analysis  gepubliceerd in BMD Cancer - BioMed Central Cancer en het volledige studierapport is gratis in te zien. Onderaan dit artikel staat abstract van deze studie plus een referentielijst van studies naar dit onderwerp

Wat is filgrastim? Bron: Apotheek.nl:

Filgrastim (Neupogen) wordt onder andere gebruikt bij mensen die een beenmergtransplantatie ondergaan, om de tijd te overbruggen tot het beenmerg voldoende witte bloedcellen aanmaakt. Verder bij mensen met een tekort aan witte bloedcellen, als aangeboren ziekte of veroorzaakt door geneesmiddelen, door hiv-aids (zie hierna) of door chemotherapie (zie hierna). Dit middel wordt ook gebruikt bij gezonde mensen om de aanmaak van witte bloedcellen te stimuleren, die dan bij hen via de bloedbaan worden afgenomen om te doneren aan iemand die tekort aan deze bloedcellen heeft.

Wat is pegfilgrastim? Bron: Oncolink.org

Pegfilgrastim (Neulasta) is een zogeheten kolonie stimulerende factor en valt in een groep van geneesmiddelen die de productie en functie van bloedcellen, waaronder witte bloedcellen, rode bloedcellen en bloedplaatjes stimuleren. Granulocyt kolonie-stimulerende factor (G-CSF) is een eiwit dat door het lichaam wordt geproduceert om de productie van witte bloedcellen te verhogen. Pegfilgrastim is een langwerkende, kunstmatige versie van G-CSF dat de productie van witte bloedcellen en in het bijzonder neutrofielen stimuleert.
Een neutrofiel is een type witte bloedcel dat verantwoordelijk is voor de bestrijding van infecties en de aanwezige neutrofielen worden vaak verminderd tijdens chemokuren in een behandeling van kanker. Wanneer het aantal van deze cellen beneden 1000/mm3, wordt dit neutropenie genoemd en heeft de patiënt een vergroot risico op infecties.
Pegfilgrastim wordt gebruikt om neutropenie gerelateerd aan chemotherapie te voorkomen of te behandelen.

Primary prophylaxis with G-CSFs significantly reduces FN incidence in adults undergoing chemotherapy for solid tumours or lymphoma. Pegfilgrastim reduces FN incidence to a significantly greater extent than filgrastim.

BMC Cancer. 2011; 11: 404.
Published online 2011 September 23. doi:  10.1186/1471-2407-11-404
PMCID: PMC3203098

Granulocyte colony-stimulating factors for febrile neutropenia prophylaxis following chemotherapy: systematic review and meta-analysis

Katy L Cooper,1 Jason Madan,2 Sophie Whyte,1 Matt D Stevenson,1 and Ron L Akehurst1
 

Abstract

Background

Febrile neutropenia (FN) occurs following myelosuppressive chemotherapy and is associated with morbidity, mortality, costs, and chemotherapy reductions and delays. Granulocyte colony-stimulating factors (G-CSFs) stimulate neutrophil production and may reduce FN incidence when given prophylactically following chemotherapy.

Methods

A systematic review and meta-analysis assessed the effectiveness of G-CSFs (pegfilgrastim, filgrastim or lenograstim) in reducing FN incidence in adults undergoing chemotherapy for solid tumours or lymphoma. G-CSFs were compared with no primary G-CSF prophylaxis and with one another. Nine databases were searched in December 2009. Meta-analysis used a random effects model due to heterogeneity.

Results

Twenty studies compared primary G-CSF prophylaxis with no primary G-CSF prophylaxis: five studies of pegfilgrastim; ten of filgrastim; and five of lenograstim. All three G-CSFs significantly reduced FN incidence, with relative risks of 0.30 (95% CI: 0.14 to 0.65) for pegfilgrastim, 0.57 (95% CI: 0.48 to 0.69) for filgrastim, and 0.62 (95% CI: 0.44 to 0.88) for lenograstim. Overall, the relative risk of FN for any primary G-CSF prophylaxis versus no primary G-CSF prophylaxis was 0.51 (95% CI: 0.41 to 0.62). In terms of comparisons between different G-CSFs, five studies compared pegfilgrastim with filgrastim. FN incidence was significantly lower for pegfilgrastim than filgrastim, with a relative risk of 0.66 (95% CI: 0.44 to 0.98).

Conclusions

Primary prophylaxis with G-CSFs significantly reduces FN incidence in adults undergoing chemotherapy for solid tumours or lymphoma. Pegfilgrastim reduces FN incidence to a significantly greater extent than filgrastim.

References

  • Kuderer N, Dale D, Crawford J, Cosler L, Lyman G. Mortality, Morbidity, and Cost Associated with Febrile Neutropenia in Adult Cancer Patients. CANCER. 2006;106:2258–2266. doi: 10.1002/cncr.21847. [PubMed] [Cross Ref]
  • Brown R, Hutton J, Burrell A. Cost Effectiveness of Treatment Options in Advanced Breast Cancer in the UK. Pharmacoeconomics. 2001;19:1091–1102. doi: 10.2165/00019053-200119110-00003. [PubMed] [Cross Ref]
  • Brown RE, Hutton J. Cost-utility model comparing docetaxel and paclitaxel in advanced breast cancer patients. Anticancer Drugs. 1998;9:899–907. doi: 10.1097/00001813-199811000-00009. [PubMed] [Cross Ref]
  • Shayne M, Crawford J, Dale D, Culakova E, Lyman G. for the ANC Study Group. Predictors of reduced dose intensity in patients with early-stage breast cancer receiving adjuvant chemotherapy. Breast Cancer Res Treat. 2006;100:255–262. doi: 10.1007/s10549-006-9254-4. [PubMed] [Cross Ref]
  • Bonadonna G, Moliterni A, Zambetti M, Daidone M, Pilotti S, Gianni L. et al. 30 years' follow up of randomised studies of adjuvant CMF in operable breast cancer: cohort study. BMJ. 2005;330:217–222. doi: 10.1136/bmj.38314.622095.8F. [PMC free article] [PubMed] [Cross Ref]
  • Welte K, Gabrilove J, Bronchud MH, Platzer E, Morstyn G. Filgrastim (r-metHuG-CSF): the first 10 years. Blood. 1996;88:1907–1929. [PubMed]
  • Green M, Koelbl H, Baselga J, GAlid A, Guillem V, Gascon P. et al. A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. Annals of Oncology. 2003;14:29–35. doi: 10.1093/annonc/mdg019. [PubMed] [Cross Ref]
  • Holmes F, O'Shaughnessy J, Vukelja S, Jones S, Shogan J, Savin M. et al. Blinded, Randomized, Multicenter Study to Evaluate Single Administration Pegfilgrastim Once per Cycle Versus Daily Filgrastim as an Adjunct to Chemotherapy in Patients With High-Risk Stage II or Stage III/IV Breast Cancer. JOURNAL OF CLINICAL ONCOLOGY. 2002;20:727–731. doi: 10.1200/JCO.20.3.727. [PubMed] [Cross Ref]
  • Chevallier B, Chollet P, Merrouche Y, Roche H, Fumoleau P, Kerbrat P. et al. Lenograstim prevents morbidity from intensive induction chemotherapy in the treatment of inflammatory breast cancer. J Clin Oncol. 1995;13:1564–1571. [PubMed]
  • Bui BN, Chevallier B, Chevreau C, Krakowski I, Peny AM, Thyss A. et al. Efficacy of lenograstim on hematologic tolerance to MAID chemotherapy in patients with advanced soft tissue sarcoma and consequences on treatment dose-intensity. J Clin Oncol. 1995;13:2629–2636. [PubMed]
  • Molineux G. The design and development of pegfilgrastim (PEG-rmetHuG-CSF, Neulasta) Curr Pharm Des. 2004;10:1235–1244. doi: 10.2174/1381612043452613. [PubMed] [Cross Ref]
  • Molineux G. Pegfilgrastim: using pegylation technology to improve neutropenia support in cancer patients. Anticancer Drugs. 2003;14:259–264. doi: 10.1097/00001813-200304000-00002. [PubMed] [Cross Ref]
  • Aapro MS, Bohlius J, Cameron DA, Dal LL, Donnelly JP, Kearney N. et al. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer. 2011;47:8–32. [PubMed]
  • Smith TJ, Khatcheressian J, Lyman GH, Ozer H, Armitage JO, Balducci L. et al. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol. 2006;24:3187–3205. doi: 10.1200/JCO.2006.06.4451. [PubMed] [Cross Ref]
  • National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology: Myeloid Growth Factors. 2011. 1-5-2010.
  • Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009;151:264–269. [PubMed]
  • PRISMA statement website. 2009. http://www.prisma-statement.org
  • Kuderer N, Dale D, Crawford J, Lyman G. Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. JOURNAL OF CLINICAL ONCOLOGY. 2007;25:3158–6731. doi: 10.1200/JCO.2006.08.8823. [PubMed] [Cross Ref]
  • Pinto L, Liu Z, Doan Q. Comparison of pegfilgrastim with filgrastim on febrile neutropenia, grade IV neutropenia and bone pain: a meta-analysis of randomized controlled trials. Curr Med Res Opin. 2007;23:2283–2295. doi: 10.1185/030079907X219599. [PubMed] [Cross Ref]
  • Higgins JPT, Green S. The Cochrane Collaboration. Cochrane Handbook for Systematic Reviews of Interventions. 2009.
  • Vogel C, Wojtukiewicz M, Carroll R, Tjulandin S, Barajas-Figueroa L, Wiens B. et al. First and Subsequent Cycle Use of Pegfilgrastim Prevents Febrile Neutropenia in Patients With Breast Cancer: A Multicenter, Double-Blind, Placebo-Controlled Phase III Study. J Clin Oncol. 2005;23:1178–1184. doi: 10.1200/JCO.2005.09.102. [PubMed] [Cross Ref]
  • Balducci L, Al-Halawani H, Charu V, Tam J, Shahin S, Dreiling L. et al. Elderly cancer patients receiving chemotherapy benefit from first-cycle pegfilgrastim. Oncologist. 2007;12:1416–1424. doi: 10.1634/theoncologist.12-12-1416. [PubMed] [Cross Ref]
  • Romieu G, Clemens M, Mahlberg R. Pegfilgrastim supports delivery of FEC-100 chemotherapy in elderly patients with high risk breast cancer: A randomized phase 2 trial. Critical Reviews in Oncology/Hematology. 2007;64:64–72. doi: 10.1016/j.critrevonc.2006.12.007. [PubMed] [Cross Ref]
  • Hecht JR, Pillai M, Gollard R, Dreiling L, Mo M, Malik I. Pegfilgrastim in colorectal cancer (CRC) patients (pts) receiving every-two-week (Q2W) chemotherapy (CT): Long-term results from a phase II, randomized, controlled study. JOURNAL OF CLINICAL ONCOLOGY. 2009;27:Abstract 4072.
  • Doorduijn JK, van der HB, van Imhoff GW, van der Hem KG, Kramer MH, van Oers MH. et al. CHOP compared with CHOP plus granulocyte colony-stimulating factor in elderly patients with aggressive non-Hodgkin's lymphoma. J Clin Oncol. 2003;21:3041–3050. doi: 10.1200/JCO.2003.01.076. [PubMed] [Cross Ref]
  • Osby E, Hagberg H, Kvaloy S, Teerenhovi L, Anderson H, Cavallin-Stahl E. et al. CHOP is superior to CNOP in elderly patients with aggressive lymphoma while outcome is unaffected by filgrastim treatment: results of a Nordic Lymphoma Group randomized trial. Blood. 2003;101:3840–3848. doi: 10.1182/blood-2002-10-3238. [PubMed] [Cross Ref]
  • Zinzani PL, Pavone E, Storti S, Moretti L, Fattori PP, Guardigni L. et al. Randomized trial with or without granulocyte colony-stimulating factor as adjunct to induction VNCOP-B treatment of elderly high-grade non-Hodgkin's lymphoma. Blood. 1997;89:3974–3979. [PubMed]
  • Pettengell R, Gurney H, Radford J, Deakin D. Granulocyte Colony-Stimulating Factor to Prevent Dose-Limiting Neutropenia in Non-Hodgkin's Lymphoma: A Randomized Controlled Trial. Blood. 1992;80:1430–1436. [PubMed]
  • Timmer-Bonte J, de Boo T, Smit H, Biesma B, Wilschut F, Cheragwandi S. et al. Prevention of Chemotherapy-Induced Febrile Neutropenia by Prophylactic Antibiotics Plus or Minus Granulocyte Colony-Stimulating Factor in Small-Cell Lung Cancer: A Dutch Randomized Phase III Study. J Clin Oncol. 2005;23:7974–7984. doi: 10.1200/JCO.2004.00.7955. [PubMed] [Cross Ref]
  • Trillet-Lenoir V, Green J, Manegold C, Von Pawel J, Gatzemeier U, Lebeau B. et al. Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy. European Journal of Cancer. 1993;29:319–324. doi: 10.1016/0959-8049(93)90376-Q. [PubMed] [Cross Ref]
  • Crawford J, Ozer H, Stoller R, Johnson D, Lyman G, Tabbara I. et al. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med. 1991;325:164–170. doi: 10.1056/NEJM199107183250305. [PubMed] [Cross Ref]
  • Fossa SD, Kaye SB, Mead GM, Cullen M, de WR, Bodrogi I. et al. Filgrastim during combination chemotherapy of patients with poor-prognosis metastatic germ cell malignancy. European Organization for Research and Treatment of Cancer, Genito-Urinary Group, and the Medical Research Council Testicular Cancer Working Party, Cambridge, United Kingdom. J Clin Oncol. 1998;16:716–724. [PubMed]
  • del Giglio A, Eniu A, Ganea-Motan D, Topuzov E, Lubenau H. XM02 is superior to placebo and equivalent to Neupogen in reducing the duration of severe neutropenia and the incidence of febrile neutropenia in cycle 1 in breast cancer patients receiving docetaxel/doxorubicin chemotherapy. BMC Cancer. 2008;8:332. doi: 10.1186/1471-2407-8-332. [PMC free article] [PubMed] [Cross Ref]
  • Gisselbrecht C, Haioun C, Lepage E, Bastion Y, Tilly H, Bosly A. et al. Placebo-controlled phase III study of lenograstim (glycosylated recombinant human granulocyte colony-stimulating factor) in aggressive non-Hodgkin's lymphoma: factors influencing chemotherapy administration. Groupe d'Etude des Lymphomes de l'Adulte. Leuk Lymphoma. 1997;25:289–300. [PubMed]
  • Gebbia V, Valenza R, Testa A, Cannata G, Borsellino N, Gebbia N. A prospective randomized trial of thymopentin versus granulocyte--colony stimulating factor with or without thymopentin in the prevention of febrile episodes in cancer patients undergoing highly cytotoxic chemotherapy. Anticancer Res. 1994;14:731–734. [PubMed]
  • Gebbia V, Testa A, Valenza R, Borsellino N, Cipolla C, Cannata G. et al. A prospective evaluation of the activity of human granulocyte-colony stimulating factor on the prevention of chemotherapy-related neutropenia in patients with advanced carcinoma. J Chemother. 1993;5:186–190. [PubMed]
  • Holmes F, Jones S, O'Shaughnessy J, Vukelja S, George T, Savin M. et al. Comparable efficacy and safety profiles of once-per-cycle pegfilgrastim and daily injection filgrastim in chemotherapy-induced neutropenia: a multicenter dose-finding study in women with breast cancer. Annals of Oncology. 2002;13:903–909. doi: 10.1093/annonc/mdf130. [PubMed] [Cross Ref]
  • Grigg A, Solal-Celigny P, Hoskin P, Taylor K, McMillan A, Forstpointner R. et al. Open-label, randomized study of pegfilgrastim vs. daily filgrastim as an adjunct to chemotherapy in elderly patients with non-Hodgkin's lymphoma. Leuk Lymphoma. 2003;44:1503–1508. doi: 10.1080/1042819031000103953. [PubMed] [Cross Ref]
  • Vose J, Crump M, Lazarus H, Emmanouilides C, Schenkein D, Moore J. et al. Randomized, Multicenter, Open-Label Study of Pegfilgrastim Compared With Daily Filgrastim After Chemotherapy for Lymphoma. JOURNAL OF CLINICAL ONCOLOGY. 2003;21:514–519. doi: 10.1200/JCO.2003.03.040. [PubMed] [Cross Ref]

literatuurlijst, voedingsupplementen, voeding, pegfilgrastim, neulasta, filgrastim, neupogen, neutropenie


Plaats een reactie ...

Reageer op "Neutropenie: Helpt neupogen of neulasta wel tegen neutropenie - tekort aan witte bloedlichaampjes - veroorzaakt door chemo? En zijn er niet toxische natuurlijke alternatieven voor?"


Gerelateerde artikelen
 

Gerelateerde artikelen

FAQ - Veel gestelde vragen >> Sitehulp. Hoe vindt u informatie >> Waar in Europa wordt nog meer >> Wim Huppes staat 18 en 20 >> Tineke geeft haar mening over >> Crowdsurfing project: Helpen >> Mevrouw B. en haar dochter >> Wat is een darmmicrobioomtest >> Wie heeft tips voor mij over >> Een neuspray en mondspray >>